Skip to main content

Table 3 Time Trade-Off Preference Values

From: Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom

Health State Main Analysis Population (n = 120) Alternate Analysis Population (n = 116) All Participants
(n = 125)
HS-1 Treatment with chemotherapy
 Mean (95% CI) 0.36 (0.28–0.43) 0.35 (0.27–0.42) 0.37 (0.30–0.45)
 Median 0.50 0.50 0.50
 Q1–Q3 0–0.60 0–0.60 0–0.60
HS-2 Consolidation
 Mean (95% CI) 0.46 (0.40–0.53) 0.46 (0.39–0.52) 0.47 (0.41–0.53)
 Median 0.50 0.50 0.50
 Q1–Q3 0.20–0.70 0.20–0.70 0.20–0.70
HS-3 Transplant
 Mean (95% CI) 0.28 (0.20–0.37) 0.27 (0.18–0.36) 0.30 (0.22–0.38)
 Median 0.50 0.50 0.50
 Q1–Q3 0–0.60 0–0.60 0–0.60
HS-4 GvHD
 Mean (95% CI) 0.43 (0.36–0.50) 0.42 (0.35–0.50) 0.44 (0.37–0.51)
 Median 0.50 0.50 0.50
 Q1–Q3 0.20–0.70 0.20–0.70 0.20–0.70
HS-5 Remission
 Mean (95% CI) 0.62 (0.57–0.67) 0.62 (0.57–0.67) 0.62 (0.57–0.67)
 Median 0.70 0.70 0.70
 Q1–Q3 0.50–0.90 0.50–0.83 0.50–0.90
HS-6 Relapse
 Mean (95% CI) 0.10 (0–0.20) 0.09 (−0.01–0.19) 0.12 (0.03–0.22)
 Median 0.10 0.10 0.10
 Q1–Q3 −0.10–0.50 − 0.10–0.50 − 0.10–0.50
HS-7 Refractory
 Mean (95% CI) −0.11 (− 0.21 to − 0.01) −0.11 (− 0.22 to − 0.01) −0.08 (− 0.18–0.02)
 Median − 0.10 −0.10 − 0.10
 Q1–Q3 −0.60–0.30 − 0.63–0.30 −0.50–0.50
HS-8 Functionally cured
 Mean (95% CI) 0.76 (0.72–0.79) 0.76 (0.72–0.80) 0.75 (0.71–0.79)
 Median 0.80 0.80 0.80
 Q1–Q3 0.70–0.90 0.70–0.90 0.70–0.90
  1. CI confidence interval, GvHD graft-versus-host disease, HS health state